Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alivid LLC is currently prosecuting a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action that requires a response. This matter is being examined by SHIN, DANA H, who is the busiest examiner for the company's active filings.
The prosecution is concentrated, with 1 distinct examiner and a distinct art unit involved in the process. SHIN, DANA H is the examiner assigned to the pending office action. Because the entire pending workload is managed by this individual, the company's legal strategy should be tailored to their specific examination style and previous office action history.
The focus on a distinct art unit indicates that the technology is being reviewed by a specialized group at the patent office. Practitioners should consider the technical standards of this unit when drafting amendments. With the pending office action representing the current focus of the portfolio, its resolution is a significant factor for the company's immediate patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558984 | A Biological Entity for Treating Brain Cancer | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558984 | A Biological Entity for Treating Brain Cancer | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558984 | A Biological Entity for Treating Brain Cancer | SHIN, DANA H | 1635 | §102§103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlivid LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dana H Shin has the most, with 1 of Alivid LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
